These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 1965481)
1. [Effect of some nonintercalative antitumor drugs on the activity of calf thymus DNA topoisomerase I]. Zhang WS; Lin ZK; Huang XT Yao Xue Xue Bao; 1990; 25(9):641-5. PubMed ID: 1965481 [TBL] [Abstract][Full Text] [Related]
2. Calf-thymus topoisomerase I equilibrates metastable secondary structure subsequent to relaxation of superhelical stress. Brewood GP; Delrow JJ; Schurr JM Biochemistry; 2010 Apr; 49(16):3367-80. PubMed ID: 20178373 [TBL] [Abstract][Full Text] [Related]
3. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Holden JA; Wall ME; Wani MC; Manikumar G Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase activity associated with polyoma virus large tumor antigen. Marton A; Marko B; Delbecchi L; Bourgaux P Biochim Biophys Acta; 1995 May; 1262(1):59-63. PubMed ID: 7772600 [TBL] [Abstract][Full Text] [Related]
5. Expression, purification and DNA-cleavage activity of recombinant 68-kDa human topoisomerase I-target for antitumor drugs. Bronstein IB; Wynne-Jones A; Sukhanova A; Fleury F; Ianoul A; Holden JA; Alix AJ; Dodson GG; Jardillier JC; Nabiev I; Wilkinson AJ Anticancer Res; 1999; 19(1A):317-27. PubMed ID: 10226561 [TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Bendetz-Nezer S; Gazit A; Priel E Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255 [TBL] [Abstract][Full Text] [Related]
7. [Effect of camptothecin on the DNA-relaxing and DNA-cleavage activity of calf thymus topoisomerase I]. Bronshteĭn IB; Gromova II; Bukhman VL; Kafiani KA Mol Biol (Mosk); 1989; 23(2):491-501. PubMed ID: 2549395 [TBL] [Abstract][Full Text] [Related]
8. Modulation of DNA topoisomerase I activity by p53. Gobert C; Bracco L; Rossi F; Olivier M; Tazi J; Lavelle F; Larsen AK; Riou JF Biochemistry; 1996 May; 35(18):5778-86. PubMed ID: 8639538 [TBL] [Abstract][Full Text] [Related]
9. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Labourier E; Riou JF; Prudhomme M; Carrasco C; Bailly C; Tazi J Cancer Res; 1999 Jan; 59(1):52-5. PubMed ID: 9892183 [TBL] [Abstract][Full Text] [Related]
10. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516 [TBL] [Abstract][Full Text] [Related]
11. Differential modulation by spermidine of reactions catalyzed by type 1 prokaryotic and eukaryotic topoisomerases. Srivenugopal KS; Morris DR Biochemistry; 1985 Aug; 24(18):4766-71. PubMed ID: 3000418 [TBL] [Abstract][Full Text] [Related]
12. A type 1 DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Chakraborty AK; Gupta A; Majumder HK Indian J Biochem Biophys; 1993 Oct; 30(5):257-63. PubMed ID: 8144168 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action. Aflalo E; Iftach S; Segal S; Gazit A; Priel E Cancer Res; 1994 Oct; 54(19):5138-42. PubMed ID: 7923131 [TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria. Lazarus GM; Henrich JP; Kelly WG; Schmitz SA; Castora FJ Biochemistry; 1987 Sep; 26(19):6195-203. PubMed ID: 2825774 [TBL] [Abstract][Full Text] [Related]
15. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Rowe TC; Chen GL; Hsiang YH; Liu LF Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716 [TBL] [Abstract][Full Text] [Related]
16. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412 [TBL] [Abstract][Full Text] [Related]
17. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995 [TBL] [Abstract][Full Text] [Related]
18. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Cline SD; Macdonald TL; Osheroff N Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572 [TBL] [Abstract][Full Text] [Related]
19. Mammalian topoisomerase I has base mismatch nicking activity. Yeh YC; Liu HF; Ellis CA; Lu AL J Biol Chem; 1994 Jun; 269(22):15498-504. PubMed ID: 8195193 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous purification of DNA topoisomerase I and II from eukaryotic cells. Strausfeld U; Richter A Prep Biochem; 1989; 19(1):37-48. PubMed ID: 2544867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]